UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
October 13, 2023
________________
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
Form 20-F [X] | Form 40-F [ ] |
Novo Nordisk raises sales and operating profit outlook for 2023
Bagsværd, Denmark, 13 October 2023 – Novo Nordisk today announced that the sales and operating profit growth at constant exchange rates (CER) for the first nine months of 2023 and that the full-year sales and operating profit outlook at CER have been raised.
In the first nine months of 2023, Novo Nordisk’s sales increased by 33% and operating profit increased by 37% both at CER.
Profit and loss (CER) | Third quarter 2023 | First nine months 2023 |
Sales growth | 38% | 33% |
Operating profit growth (EBIT) | 47% | 37% |
The sales outlook for 2023 is updated, primarily reflecting higher full-year expectations for Ozempic® volumes sold in the US and gross-to-net sales adjustments for Ozempic® and Wegovy® in the US.
Outlook 2023 (CER) | Expectations 10 August | Expectations 13 October |
Sales growth | 27-33% | 32-38% |
Operating profit growth (EBIT) | 31-37% | 40-46% |
Novo Nordisk’s full disclosure of the financial results for the first nine months of 2023 will be published on 2 November 2023.
The above expectations are based on assumptions including those described on pages 15 and 16 of the Financial report for the period 1 January 2023 to 30 June 2023 (Company Announcement No 52/2023).
The forward-looking statements on page 22 of the Financial report for the period 1 January 2023 to 30 June 2023 (Company Announcement No 52/2023) also apply to this company announcement.
Page 2 of 2
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 59,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube.
Contacts for further information
Media: | |
Ambre James-Brown +45 3079 9289 abmo@novonordisk.com | Elizabeth DeLuca (US) +1 609 580 9868 edel@novonordisk.com
|
Investors: | |
Daniel Muusmann Bohsen +45 3075 2175 dabo@novonordisk.com | Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com
|
David Heiberg Landsted +45 3077 6915 dhel@novonordisk.com | Sina Meyer +45 3075 6656 azey@novonordisk.com
|
Frrederik Taylor Pitter +45 3075 8259 fptr@novonordisk.com |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | Internet: 24 25 67 90 |
Company announcement No 64 / 2023 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: October 13, 2023 |
NOVO NORDISK A/S
Lars Fruergaard Jørgensen Chief Executive Officer |